Table 3.
A | ||||||||
rBet v 1-FV | Threshold response after treatment in 1st year | |||||||
BU/mL | 555 | 1,666 | 5,000 | 15,000 | 45,000 | 150,000 | negative | |
Threshold response at baseline | 555 | 3 | 3 | 0 | 0 | 0 | 0 | 1 |
1,666 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | |
5,000 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
15,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
45,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
rBet v 1-FV | Threshold response after treatment in 2nd year | |||||||
BU/mL | 555 | 1,666 | 5,000 | 15,000 | 45,000 | 150,000 | negative | |
Threshold response at baseline | 555 | 0 | 4 | 0 | 2 | 0 | 0 | 0 |
1,666 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | |
5,000 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | |
15,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
45,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
B | ||||||||
Comparator | Threshold response after treatment in 1st year | |||||||
BU/mL | 555 | 1,666 | 5,000 | 15,000 | 45,000 | 150,000 | negative | |
Threshold response at baseline | 555 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
1,666 | 2 | 2 | 3 | 1 | 0 | 0 | 0 | |
5,000 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | |
15,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
45,000 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
Comparator | Threshold response after treatment in 2nd year | |||||||
BU/mL | 555 | 1,666 | 5,000 | 15,000 | 45,000 | 150,000 | negative | |
Threshold response at baseline | 555 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
1,666 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | |
5,000 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | |
15,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
45,000 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Data indicate numbers of subjects and their responses at baseline compared with that after 1 year or 2 years of treatment with (A) rBet v 1-FV or (B) comparator
Bold printed numbers represent no change in response, and data to the right or the left an increase or decrease in tolerance respectively